In the metastatic setting, there are few retrospective data showing some degree of activity of TKIs with anti-angiogenic properties, such as sunitinib, regorafenib, and pazopanib, likely because of the pseudohypoxic phenotype of SDH-deficient GIST [32,46,47,48]. This evidence concerns the gene SDHB and gastrointestinal stromal tumor.